CN106974903A - Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared - Google Patents
Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared Download PDFInfo
- Publication number
- CN106974903A CN106974903A CN201610030801.1A CN201610030801A CN106974903A CN 106974903 A CN106974903 A CN 106974903A CN 201610030801 A CN201610030801 A CN 201610030801A CN 106974903 A CN106974903 A CN 106974903A
- Authority
- CN
- China
- Prior art keywords
- lobaplatin
- trophoblastic tumor
- prepared
- application
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Abstract
The invention provides application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared, described lobaplatin formulation is freeze drying powder injection, small-volume injection or high-capacity injection, and effective therapeutic dose is 30-60mg/m2Body surface area；There is the lobaplatin and its preparations of the present invention stronger anti-malignant trophoblastic tumor to act on, and significantly, low toxicity, safety, the treatment for malignant trophoblastic tumor provides new effective means and expanded the clinical practice of lobaplatin and its preparation therapeutic effect.
Description
Technical field
The present invention relates to a kind of new opplication of lobaplatin, it is specifically related to a kind of lobaplatin and is preparing treatment malignant trophoblastic tumor medicine
Application in thing.
Technical background
Trophoblastic tumor is embryonic feeder cells canceration, and this kind of tumour includes invasive hydatidiform mole, choriocarcinoma and tire
Pan portion position trophoblastic tumor, and choriocarcinoma includes gestational suede cancer and non-gestational choriocarcinoma, non-gestational choriocarcinoma is rare,
But can occur after mediastinum peritonaeum, ovary, lung, oesophagus, stomach, liver, abdominopelvic cavity etc..The trophocyte cause of disease is unclear, can
Can be different with malnutritive (being especially the absence of high-quality animal protein diet), virus infection, ovarian dysfunction and ovum
Often, chromosome abnormality, immunologic dysfunction, ethnic group, geography, weather and ambient influnence are relevant.Trophoblastic tumor is
It is findable tumour that a few, which not exclusively relies on pathological section,.Oncocyte can be transferred to lung, vagina with blood, brain, lead
Cause patient's massive hemoptysis, colporrhagia, unexpected blindness, aphasia and intracranial hemorrhage and threat to life.
Malignant trophoblastic tumor is insensitive to radiotherapy, and the treatment effective therapy approach of malignant trophoblastic tumor is that chemotherapy is at present
It is main, supplemented by operative treatment.Therefore, chemotherapeutics is most important to treatment malignant trophoblastic tumor, determines the key of curative effect
It is the selection of chemotherapeutics.But nowadays, the effective chemotherapeutics for treating malignant trophoblastic tumor is less, lacks more steady
Fixed, the more preferable chemotherapeutics of safer and therapeutic effect.
Lobaplatin (Lobaplatin, D-19466) also known as lobaplatin, be after cis-platinum, carboplatin by German Ace up to pharmacy stock
The third generation platinum series antineoplastic medicament of part Co., Ltd (ASTA Medica AG) research and development.Its chemical name is：1,2- bis-
Methyl-cyclobutane-lactic acid closes platinum.Molecular formula is C9H18N2O3Pt, and molecular weight is 397.34.
Present invention applicant respectively number of patent application be CN201010556219.1, it is entitled " a kind of that Lip river is prepared with oxalates
The method of platinum trihydrate " and number of patent application be CN201010500619.0, it is entitled " a kind of anti-tumor medicinal preparation
The preparation method of lobaplatin trihydrate and the preparation method of injection lobaplatin are disclosed in the patent of invention of preparation method ".
The prior art indicate that, lobaplatin has clear and definite CDCC to many animals and human tumor cell line, the tumor suppression with cis-platinum
Effect quite or more preferably, overcomes renal toxicity, the gastrointestinal toxicity of cis-platinum, bone marrow suppression is lighter than carboplatin, and with cis-platinum without
Crossing drug resistant.Lobaplatin side effect is lower than cis-platinum and carboplatin, and antitumor activity is strong, and toxicity is smaller, and safety, solubility is good,
It is stable in water, it is mainly used in the treatment of breast cancer, ED-SCLC and chronic granulocytic leukemia.
Although research before shows that lobaplatin can be used for preparing treatment breast cancer, ED-SCLC and the white blood of chronic granulocytic
The various disease conditions such as disease, but have no the patent document for utilizing lobaplatin and its preparation to the therapeutic action in terms of malignant trophoblastic tumor
With research report.The applicant has found that lobaplatin and its preparation can be used for malignant trophoblastic tumor in subsequent research
Treatment.
The content of the invention
It is an object of the invention to provide a kind of new opplication of lobaplatin, substantially lobaplatin is preparing treatment malignant trophoblastic tumor
Application in medicine.
Effective therapeutic dose of described lobaplatin is 30-60mg/m2Body surface area, preferred therapeutic amount is 40-50mg/m2Body surface area,
Most preferred therapeutic dose is 40mg/m2Body surface area.
Described platinum prepare treatment malignant trophoblastic tumor medicine in application be freeze drying powder injection is made in lobaplatin, it is small
Volume injection liquid or high-capacity injection.It is preferred that freeze drying powder injection.
In use, pharmaceutically conventional carrier can be added or be added without as needed, such as excipient, stabilizer, surface are lived
Property agent, conditioning agent etc., required formulation is prepared into according to the conventional method of pharmaceutical field.
Foregoing lobaplatin preparation method of administration is administered for intravenous injection.
Lobaplatin of the present invention and injection lobaplatin can be marketed products, can also be according to number of patent application CN201010556219.1
Or prepared by method in CN201010500619.0.
Lobaplatin is newest third generation platinum-based chemotherapy medicine, compared with cis-platinum (first generation), carboplatin (second generation), to malignant tumour
Therapeutic effect quite or more preferably, and smaller to human toxicity, side effect is minimum, safer.Lobaplatin antitumor spectra is extensive,
It is effective to multiple cancer kinds.Lobaplatin has significant curative effect to treatment malignant trophoblastic tumor, its Small side effects, clinical application
It is safer.The further experimental study of the applicant finds that lobaplatin really can be used for preparing treatment malignant trophoblastic tumor
Medicine.
Embodiment
In order that those of ordinary skill in the art are better understood from the present invention, the present invention is expanded on further by the following examples
Experimental study of the lobaplatin in treatment Trophoblastic tumor medicine.It should be noted that：Following examples are only to explain this hair
It is bright, rather than the limitation present invention.
Embodiment 1：The activity research of the external anti-trophoblastic tumor cell of lobaplatin
1.1 materials and reagent
1.1.1 medicine name and source：Lobaplatin is white freeze-dried powder, Hainan Chang'an International Pharmaceutical Co., Ltd；Carboplatin is white
Color powder, Kunming Guiyan Pharmaceutical Co., Ltd.；5 FU 5 fluorouracil, Xi'an Hai Xin pharmaceutical Co. Ltds；Cis-platinum is yellow powder,
Jiangsu Haosen Pharmaceutical Co., Ltd.
Compound method：Above medicine is made into respective concentration with serum free medium.
1.1.2 cell line
People's Trophoblastic JEG-3 cells and jar cell, purchased from Institute of Botany family planning biology of reproduction state of the Chinese Academy of Sciences
Key lab of family, according to the specification culture provided.
1.1.3 reagent and instrument
DMEM/F12(1:1) culture medium, hyclone (Gibco companies of the U.S.), penicillin (100u/L), streptomysin (100
μ g/mL), 0.25% trypsase CO2Incubator, ELx800 types ELIASA (Bio-Tek companies of the U.S.).
1.2 research method
1.2.1 cell culture
With the DMEM/F12 (1 containing 10% hyclone, 100u/L penicillin and 100 μ g/mL streptomysins:1) culture medium,
In 37 DEG C, 5%CO2Routine passage culture JEG-3 cells and jar cell in incubator, 2-3 days had digestive transfer cultures once (0.25%
Pancreatin contains EDTA).
1.2.2 cell inhibitory rate is determined
Take the logarithm growth period JEG-3 cell and jar cell, with being collected after 0.25% pancreatin digestion, cell count adjustment is thin
Born of the same parents' concentration.It is inoculated in by every 6 × 104 cells in hole on 24 hollow plates, often place sets three multiple holes.In 5%CO2,37 DEG C
It is incubated 12 hours, medicine sets 5-7 concentration respectively, and each concentration sets 3 multiple holes, continuous action is after 18 hours, per hole
MTT solution (5mg/ml) 100 μ l are added, continue to cultivate 4 hours.Culture is terminated, supernatant is carefully sucked, added per hole
400 μ l dimethyl sulfoxide (DMSO)s (DMSO), are placed in low-speed oscillation 30min on shaking table, crystal is fully dissolved.With ELIASA
Optical density (OD) is determined at 493nm wavelength.Blank control is replaced with fresh serum-free media.Calculate Drug inhibition rate
And half-inhibition concentration (IC50)：
Drug inhibition rate (%)=(blank control OD- medication OD)/blank control OD × 100%
Half-inhibition concentration (IC50)：Refer to the concentration of inhibitor when being suppressed half, i.e. apoptotic cell and whole cell numbers it
Corresponding concentration during than equal to 50%.Inducibility is stronger, and the numerical value is lower.
1.3 result of the test
It can substantially suppress external trophoblastic tumor JEG-3 when the lobaplatin of various dose, cis-platinum, carboplatin and alone 5 FU 5 fluorouracil
The propagation of cell and jar cell, wherein lobaplatin dosage are 20-40mg/m2When, inhibiting rate journey increasing trend and be incremented by amplitude it is bright
It is aobvious；Lobaplatin dosage is 40-60mg/m2When, inhibiting rate is slowly incremented by, when lobaplatin dosage is 70mg/m2When, its inhibiting rate is protected
Maintain an equal level steady, no longer increase.Lobaplatin dosage is 20mg/m2When, drug concentration is too low, inhibitory action be weaker than cis-platinum, carboplatin and
5 FU 5 fluorouracil.Lobaplatin dosage is 30-70mg/m2When, inhibitory action is significantly better than cis-platinum, carboplatin and 5 FU 5 fluorouracil.Tool
Body the results are shown in Table 1 and table 2：
The lobaplatin of table 1, cis-platinum, carboplatin and 5 FU 5 fluorouracil suppress to external trophoblastic tumor JEG-3 cells and jar cell
Rate (%) result
Cis-platinum, carboplatin and 5 FU 5 fluorouracil are optimal inhibition concentration.
The lobaplatin of table 2, cis-platinum, carboplatin and 5 FU 5 fluorouracil are to external trophoblastic tumor JEG-3 cells and jar cell half
Number inhibition concentration (IC50) result
| Cell line | JEG-3 cells | Jar cell |
| Medicine name | Half-inhibition concentration (μM) | Half-inhibition concentration (μM) |
| 5 FU 5 fluorouracil | 21.7 | 20.8 |
| Carboplatin | 80.4 | 80.5 |
| Cis-platinum | 20.3 | 18.2 |
| Lobaplatin | 15.7 | 16.1 |
1.4 experiment conclusion
When various dose lobaplatin, cis-platinum, carboplatin and alone 5 FU 5 fluorouracil to external trophoblastic tumor JEG-3 cells and
The propagation of jar cell and growth have inhibitory action, and inhibitory action has obvious dose-dependence.Wherein lobaplatin dosage is
20-40mg/m2When, inhibiting rate journey increasing trend and be incremented by amplitude it is obvious；Lobaplatin dosage is 40-60mg/m2When, inhibiting rate delays
It is slow to be incremented by, when lobaplatin dosage is 70mg/m2When, its inhibiting rate held stationary no longer increases.Lobaplatin dosage is 30-70mg/m2
When, inhibitory action is significantly better than cis-platinum, carboplatin and 5 FU 5 fluorouracil, and the lobaplatin in the range of this dosage is respectively provided with significantly
The outer trophoblastic tumor JEG-3 cells of antibody and jar cell proliferation function.Lobaplatin dosage is 20mg/m2When, medicine is dense
Degree is too low, and inhibitory action is weaker than cis-platinum, carboplatin and 5 FU 5 fluorouracil.Therefore, lobaplatin suppression Trophoblastic preferred dose is
30-60mg/m2, most preferred dose is 40mg/m2。
Example 2 is applied in examination：Lobaplatin is studied the interior curative effect of trophoblastic tumor
2.1 materials and reagent：
2.1.1 medicine name and source：Lobaplatin is white freeze-dried powder, Hainan Chang'an International Pharmaceutical Co., Ltd；Carboplatin is white powder
End, Kunming Guiyan Pharmaceutical Co., Ltd.；5 FU 5 fluorouracil, Xi'an Hai Xin pharmaceutical Co. Ltds；Cis-platinum is yellow powder, river
Su Haosen medicine companies limited company.
2.1.2 experimental animal and cell
SCID beige female mices (3-5 week old, weight 16-20g), tie up the magnificent experimental animal technology of tonneau limited purchased from Beijing
Company；People trophoblastic tumor cell line JAR, purchased from the biological product collecting center (ATCC) of Unite States Standard, slow virus empty carrier
GV208, element orders：Ubi-MCS-EGFP, eucaryon resistance：Puromycin, fluorescence labeling：EGFP, purchased from Ji Kaiji
Cause, Shanghai；Polybrene is purchased from Shanghai Ji Kai companies.
2.1.3 reagent and instrument
DMEM/F12(1:1) culture medium, hyclone (Gibco companies of the U.S.), penicillin (100u/L), streptomysin (100 μ
G/mL), 0.5% pancreatin inverted microscope, CO2Incubator, pipette, rubber pipette bulb, alcolhol burner.
2.2 test method
2.2.1 cell culture
Jar cell is inoculated in the DMEM nutrient solutions containing 10% hyclone, 100u/L streptomysins and 100 μ g/mL penicillin,
In 37 DEG C, the 5%CO of saturated humidity2Secondary Culture in incubator.
2.2.2 the preparation of injection cell suspension
Selection exponential phase cell is inoculated in 6 orifice plate culture dishes, 37 DEG C, 5%CO224h is cultivated in saturated humidity incubator,
Appropriate virion and Polybrene are added into 3mL culture mediums, final concentration of 6~8 μ g/mL, featheriness is mixed, and adds culture
Ware.Fresh complete medium culture 48h is changed after 24h；Every 2 days change 2 μ g/mL puromycin medicines culture medium after
Continuous culture.After resisting cell is covered with, cell, horizontal centrifuge is resuspended in 0.5% pancreatin digestion, the culture medium containing 10% serum
1000r/min centrifuges 5min, and sterilizing PBS is resuspended cell, softly rinsed 3 times, and it is thin that progress after cell is resuspended in serum free medium
Born of the same parents are counted, after centrifuging again, and serum free medium is added according to cell number, configure 2.5 × 107/mL cell suspensions.
2.2.3 model is set up and is administered
The μ L cell suspensions of SCID beige female mices dorsal sc injection 200, treat knurl volume growth to 100~300mm3It
Between after, animal is randomly divided into saline control group (NS groups), 5 FU 5 fluorouracil, cis-platinum group, carboplatin group and lobaplatin group.
Every group 5,5 FU 5 fluorouracil group is injected intravenously 5 FU 5 fluorouracil 10mg/kg, 2 times/week, continuous two weeks daily.Cis-platinum group is every
Day intravenous injection cis-platinum 5mg/kg, 1 times/week, continuous two weeks.The daily same time intravenous injection carboplatin 100mg/m of carboplatin group2
Body surface area, 1 times/week, continuous two weeks；Lobaplatin group (is seen below by the daily same time intravenous injection lobaplatin of different dosing dosage
Table), 1 times/week, continuous two weeks.The daily same time intravenous injection NS5ml of control group.2-3 knurl volume is surveyed weekly, is claimed
Mouse weight, record data.Calculate gross tumor volume (TV), relative tumour volume (RTV) and tumour inhibiting rate (IR).
Gross tumor volume (TV)=1/2 × a (major diameter) × b2(wide footpath)
Relative tumour volume (RTV)=Vt/V0 (gross tumor volume measured when V0 is administered for packet in formula, when Vt is each measurement
Gross tumor volume)
Tumour inhibiting rate (IR) %=(1-5- fluorouracils group or the average knurl weight of the average knurl weight/NS groups of lobaplatin group or cis-platinum group or carboplatin group)
× 100%
2.2.4 result of the test
5 FU 5 fluorouracil, cis-platinum, carboplatin and various dose lobaplatin it is alone when have therapeutic effect, energy to trophoblastic tumor
Substantially suppress the growth of trophoblastic tumor；Wherein lobaplatin dosage is 20-40mg/m2When, tumour inhibiting rate journey increasing trend and be incremented by
Amplitude is obvious；Lobaplatin dosage is 40-60mg/m2When, tumour inhibiting rate is slowly incremented by, when lobaplatin dosage is 70mg/m2When, its tumor suppression
Rate held stationary, no longer increases.Lobaplatin dosage is 20mg/m2When, drug concentration is too low, and curative effect is controlled to trophoblastic tumor
Fruit is weaker than cis-platinum, carboplatin and 5 FU 5 fluorouracil.Lobaplatin dosage is 30-70mg/m2When, to the therapeutic effect of trophoblastic tumor
It is significantly better than cis-platinum, carboplatin and 5 FU 5 fluorouracil.In addition, lobaplatin dosage is 70mg/m2During body surface area, due to administration
There is lassitude and symptoms of emesis in concentration highest a, mouse.
The 5 FU 5 fluorouracil of table 1, cis-platinum, carboplatin and various dose lobaplatin are to trophoblastic tumor jar cell growth inhibition curative effect
Note：d0：First time administration time；dn：20 days after being administered for the first time；Cis-platinum, carboplatin and 5 FU 5 fluorouracil are optimal administration
Concentration.
2.3 conclusion (of pressure testing)
5 FU 5 fluorouracil, cis-platinum, the lobaplatin of carboplatin and various dose have when being administered alone to trophoblastic tumor significantly to be controlled
Therapeutic effect, can substantially suppress the growth of trophoblastic tumor；Wherein lobaplatin dosage is 20-40mg/m2When, tumour inhibiting rate journey is incremented by
Trend and be incremented by amplitude it is obvious；Lobaplatin dosage is 40-60mg/m2When, tumour inhibiting rate is slowly incremented by, when lobaplatin dosage is 70mg/m2
When, its tumour inhibiting rate held stationary no longer increases.Lobaplatin dosage is 20mg/m2When, drug concentration is too low, swollen to trophocyte
The therapeutic effect of knurl is weaker than cis-platinum, carboplatin and 5 FU 5 fluorouracil.Lobaplatin dosage is 30-70mg/m2When, to trophoblastic tumor
Therapeutic effect be significantly better than cis-platinum, carboplatin and 5 FU 5 fluorouracil, but lobaplatin dosage is 70mg/m2During body surface area,
Drug concentration is too high, and substantially, therefore, the present invention preferably lobaplatin dosage is 30-60mg/m to toxic side effect2When, nourished for treatment
The effective therapeutic dose of cytoma；Most preferably lobaplatin dosage is 40mg/m2Body surface area.
Embodiment 3：Lobaplatin treats the clinical test of malignant trophoblastic tumor
3.1 case selection：Diagnosed by the classical symptom of clinically malignant trophoblastic tumor, in conjunction with HCG (human chorionics
Promoting sexual gland hormone) detection, the multiple inspection such as B ultrasound and CT make a definite diagnosis, and filters out the patient clarified a diagnosis as malignant trophoblastic tumor
15, according to UICC TNM stages, in III phase 5, IV phase 10.All patient KPS scorings are more than 60.By 15 trouble
Person is randomly divided into two groups, treatment group 8, is all women, age 26-45 Sui, average 34.3 years old, in III phase 2, IV
Phase 6；Control group 6, is all women, age 23-47 Sui, average 35.9 years old, in III phase 3, IV phase 4.Two
Group is respectively provided with comparativity in terms of age, sex, the course of disease, the state of an illness.Patient's hepatic and renal function, blood routine are normal before treatment, in advance
Family planning was deposited more than 3 months.
3.2 treatment method：Control group gives injection and selects 5 FU 5 fluorouracil 26mg/kgd and dactinomycin D 6mg/kgd to join
Application is closed, each to add intravenous infusion in 5%G.S500ml, 5 days once, Cisplatin instillation 3mg/kg, weekly, the course for the treatment of 3
In week, be a cycle, 2 periodic recording result of the tests.Treatment group drip-feed lobaplatin 40mg/m2, weekly, the course for the treatment of 3 weeks,
For a cycle, 2 periodic recording result of the tests.
3.3 decision method：Curative effect is evaluated by RECIST evaluation criterions：(PR) is alleviated in complete incidence graph (CR), part, surely
Fixed (SD), is in progress (PD) and unchanged (NC).Efficient (RR) is calculated with CR+PR, disease control is calculated with CR+PR+SD
Rate (DCR).Quality of life assessment is using KPS scorings as standard, and scoring rises more than 10 points to improve after treatment, is within 10 points
Stable, it is reduction to reduce more than 10 points.
3.4 result
3.4.1 short term effect：Efficient (CR+PR) is 87.5% in treatment group 7, and disease control rate (CR+PR+SD) is 100.0%；
Control group effective percentage (CR+PR) is 71.4%, and disease control rate (CR+PR+SD) is 85.7%；Treatment group's short term effect is better than
Control group.Two groups of short term effects are relatively shown in Table 1.
1 two groups of patient's short term effects of table compare
| Group | Number of cases | CR | PR | SD | PD | RR (%) | DCR (%) |
| Treatment group | 8 | 3 | 4 | 1 | 0 | 87.5 | 100.0 |
| Control group | 7 | 3 | 2 | 1 | 1 | 71.4 | 85.7 |
3.4.2 recent quality of life：There are 6 (75.0%) patients ' life qualities to be improved in treatment group, matter of being lived in control group
Amount is improved as 4 (57.1%), and treatment group's patients ' life quality is better than control group.Two groups of recent qualities of life of patient are relatively shown in Table
Two.
2 two groups of recent qualities of life of patient of table compare
| Group | Number of cases | Improve (%) | Stable (%) | Decline (%) |
| Treatment group | 8 | 6 (75.0%) | 2 (25.0%) | 0 (0%) |
| Control group | 7 | 4 (57.1%) | 2 (28.6%) | 1 (14.3%) |
3.4.3 discuss：Understand from the above, the curative effect for the treatment of group and the quality of life of patient are superior to control group, and lobaplatin is made
It is better than 5 FU 5 fluorouracil, cis-platinum and dactinomycin D drug combination for treatment malignant trophoblastic tumor medicine.Illustrate lobaplatin to evil
Property trophoblastic tumor has good curative effect and potential therapeutic value.
Claims (8)
1. application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared.
2. application of the lobaplatin according to claim 1 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Effective therapeutic dose of lobaplatin is：30-60mg/m2Body surface area.
3. application of the lobaplatin according to claim 2 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Effective therapeutic dose of lobaplatin is 40-50mg/m2Body surface area.
4. application of the lobaplatin according to claim 3 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Effective therapeutic dose of lobaplatin is 40mg/m2Body surface area.
5. application of the lobaplatin according to claim 1 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Described application is that lobaplatin is made into freeze drying powder injection, small-volume injection or high-capacity injection.
6. application of the lobaplatin according to claim 5 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Described lobaplatin formulation is freeze drying powder injection.
7. application of the lobaplatin according to claim 5 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：Described freeze drying powder injection, small-volume injection or high-capacity injection is by adding or being not added with
Enter pharmaceutically conventional carrier to be prepared from using conventional method, carrier is conventional such as excipient, stabilizer, surface
Activating agent, conditioning agent.
8. application of the lobaplatin according to claim 5 in treatment malignant trophoblastic tumor medicine is prepared, its
It is characterised by：The method of administration of the lobaplatin preparation is administered for intravenous injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610030801.1A CN106974903A (en) | 2016-01-18 | 2016-01-18 | Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610030801.1A CN106974903A (en) | 2016-01-18 | 2016-01-18 | Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106974903A true CN106974903A (en) | 2017-07-25 |
Family
ID=59340169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610030801.1A Withdrawn CN106974903A (en) | 2016-01-18 | 2016-01-18 | Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974903A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111718377A (en) * | 2019-03-19 | 2020-09-29 | 海南长安国际制药有限公司 | Platinum substance with structural formulas H1 and H2, preparation and application thereof |
| CN111718375A (en) * | 2019-03-19 | 2020-09-29 | 海南长安国际制药有限公司 | Platinum substance with G1 and G2 structures and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505450A (en) * | 2012-06-25 | 2014-01-15 | 贵州益佰制药股份有限公司 | Application of lobaplatin in preparation of drugs used for treating prostate cancer |
-
2016
- 2016-01-18 CN CN201610030801.1A patent/CN106974903A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505450A (en) * | 2012-06-25 | 2014-01-15 | 贵州益佰制药股份有限公司 | Application of lobaplatin in preparation of drugs used for treating prostate cancer |
Non-Patent Citations (2)
| Title |
|---|
| 刘宗文 等: "《实用常见肿瘤的诊断与综合治疗》", 30 September 2012, 郑州大学出版社 * |
| 王缨 等: "第三代铂类抗肿瘤药物洛铂(Lobaplatin)", 《齐鲁药事》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111718377A (en) * | 2019-03-19 | 2020-09-29 | 海南长安国际制药有限公司 | Platinum substance with structural formulas H1 and H2, preparation and application thereof |
| CN111718375A (en) * | 2019-03-19 | 2020-09-29 | 海南长安国际制药有限公司 | Platinum substance with G1 and G2 structures and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160346334A1 (en) | Exosomes as a therapeutic for cancer | |
| BRPI0808635A2 (en) | Nanoparticle Understanding Rapamycin And Albumin As An Anti-Cancer Agent | |
| CN103997894A (en) | Treatment of breast cancer | |
| AU2011290818B2 (en) | Combination anti - cancer therapy | |
| CN108064172A (en) | Cell death induction reagent, cell inhibitory effect reagent and for treat by the extremely caused disease of cell Proliferation medical composition | |
| AU2015267897A1 (en) | Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same | |
| TW201330845A (en) | Therapeutic agent for pancreatic cancer and/or biliary tract cancer | |
| CN106943432A (en) | A kind of excretion body in umbilical cord mesenchymal stem cells source and its application in treatment liver-cancer medicine is prepared | |
| CN109700799A (en) | Antrocin and its micro-nano granules are preparing the application in immunotherapy of tumors drug | |
| CN108498497A (en) | Pharmaceutical composition for treating kidney and its application | |
| CN106974903A (en) | Application of the lobaplatin in treatment malignant trophoblastic tumor medicine is prepared | |
| WO2013071696A1 (en) | Use of five normal bases in humans for preparation of tumour drugs | |
| KR102011105B1 (en) | pharmaceutical composition for prevention or treatment of pancreatic cancer comprising a gossypol and a phenformin | |
| CN111712245A (en) | Therapeutic agent for hepatocellular carcinoma | |
| CN108303552A (en) | Detection method of the cucoline to pancreatic carcinoma SW1990 Proliferation and apoptosis | |
| CN102441168A (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| JP2022529949A (en) | Alkyl TPP compounds for mitochondrial targeting and anti-cancer treatment | |
| WO2023104151A1 (en) | Pharmaceutical composition for treating tumors and use | |
| CN114010789B (en) | Application of bufadienolide compound in preparing medicament for treating EGFR and/or STAT3 driving diseases | |
| CN112979753B (en) | C-Met-targeted polypeptide and application thereof | |
| CN113893350A (en) | Composition for treating cancer and application and medicine thereof | |
| CN102631345A (en) | Medicine composition for reversing cancer cell tolerance and application of medicine composition | |
| CN106974902A (en) | Application of the lobaplatin in treatment MPM medicine is prepared | |
| CN112569240A (en) | Application of chlorpromazine hydrochloride in preparation of cyclin inhibitor | |
| CN113318112A (en) | Anti-tumor medicine composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170725 |
|
| WW01 | Invention patent application withdrawn after publication |